The effect of the applied induction immunosuppressive therapy protocol on the allografted kidney condition

Aim: To assess the Eculizumab effect on the allografted kidney function in the immediate and early postoperative period.

Materials and methods: In kidney transplantation, 33 patients received Eculizumab in combination with Alemtuzumab (group 1). Other 38 patients (group 2) were enrolled for a comparative analysis. They received their induction immunosuppressive therapy with Alemtuzumab and plasmapheresis sessions. The following parameters were used for analysis: the urine output in the first 24 hours after surgery, the period of creatinine level drop to 3 mg/dL, a 24-hour protein excretion at day 30 after surgery, a glomerular filtration rate at day 30 after transplantation, histology of kidney allograft biopsy at 1 month post surgery.

Results: A comparative analysis has demonstrated much lower values of 24 hour proteinuria in group 1 than in group 2. As to the glomerular filtration rate, it was 1.9 times higher in group 1 than in group 2. The period of blood creatinine subnormalization was significantly shorter in group 1. The differences were statistically significant in all studied parameters (p=0.002–0.003).

Conclusion: The allografted kidney function was much better in group 1 than in group 2. Thus, the combination of Eculizumab + Alemtuzumab had a more favorable effect on the function and morphology of allografted kidneys in the immediate and early postoperative periods compared to that of Alemtuzumab + plasmapheresis combination.

1. Castro M.C., Arauho L.M., Nahan W.K., et al. Induction versus noninduction therapy in kidney transplantation: Considering different PRA levels and different induction therspies. Transplant Proc. 2004;36(4):874–876. PMID:15194299 DOI:10.1016/j.transproceed.2004.03.084

2. Cherikh W.S., Kauffman H.M., McBride M.A., et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorders, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76(9):1289– 1293. PMID:14627905 DOI:10.1097/01.TP.0000100826.58738.2B

3. Parlolla V., Zhong X., Reed G.W., Mandelbrot D.A. Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation. Am J Transplant. 2007;7(7):1832–1842. PMID:17564638 DOI:10.1111/j.1600-6143.2007.01860.x

4. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antilymphocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation. 2004;78(4):584–590. PMID:15446319

5. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357(25):2562–2575. PMID:18094377 DOI:10.1056/NEJMoa067411

6. Haro J.M., Kontodimas S., Negrin M.A., et al. Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy. 2006;5(1):11–25. PMID:16774289

7. Buchanan P.M., Schnitzler M.A., Brennan D.C., et al. Novel methods for tracking long-term maintenance immunosuppression regimens. Clin J Am Soc Nephrol. 2008;3(1):117–124. PMID:18077785 DOI:10.2215/CJN.02790707

8. Kaabak M.M., Babenko N., Kuznetsov O., et al. Eculizumab reverses the potentially fatal effects of kidney graft reperfusion injury. Pediatr Transplant. 2014;18(2):E44–E47. PMID:24330127 DOI: 10.1111/petr.12206.

9. Kaabak M.M., Goryaynov V.A., Zokoev A.K., et al. Ten-year experience with plasmapheresis early after kidney transplantation. Russian Journal of Transplantology and Artificial Organs. 2009;(1):28–33. (In Russian).